What is Zacks Research's Forecast for Stryker Q2 Earnings?

Stryker Co. (NYSE:SYK - Free Report) - Zacks Research reduced their Q2 2025 earnings per share estimates for Stryker in a research note issued on Thursday, May 22nd. Zacks Research analyst I. Bandyopadhyay now expects that the medical technology company will post earnings per share of $3.06 for the quarter, down from their prior forecast of $3.15. The consensus estimate for Stryker's current full-year earnings is $13.47 per share. Zacks Research also issued estimates for Stryker's Q3 2025 earnings at $3.13 EPS, FY2025 earnings at $13.29 EPS, Q1 2026 earnings at $3.05 EPS, Q2 2026 earnings at $3.28 EPS, Q3 2026 earnings at $3.28 EPS, Q4 2026 earnings at $4.78 EPS, Q1 2027 earnings at $3.92 EPS and FY2027 earnings at $16.55 EPS.

Several other equities analysts have also commented on the company. Citigroup reissued a "buy" rating and set a $455.00 price objective (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Barclays raised their price objective on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Roth Mkm raised their price objective on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Needham & Company LLC reissued a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Finally, JMP Securities reissued a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $427.30.

Stryker Trading Down 0.9%

SYK stock traded down $3.53 on Monday, reaching $380.25. The company's stock had a trading volume of 1,158,176 shares, compared to its average volume of 1,346,659. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market cap of $145.14 billion, a PE ratio of 49.00, a PEG ratio of 2.93 and a beta of 0.93. The business has a fifty day simple moving average of $368.24 and a two-hundred day simple moving average of $376.20. Stryker has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. During the same quarter last year, the firm posted $2.50 earnings per share. The firm's revenue was up 11.9% on a year-over-year basis.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's payout ratio is 45.41%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stryker

Large investors have recently bought and sold shares of the business. Elefante Mark B bought a new stake in Stryker in the 4th quarter worth about $337,000. Chicago Capital LLC increased its holdings in Stryker by 3.1% in the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after buying an additional 5,841 shares in the last quarter. Appleton Partners Inc. MA increased its holdings in Stryker by 5.0% in the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock worth $10,521,000 after buying an additional 1,400 shares in the last quarter. Metis Global Partners LLC increased its holdings in Stryker by 10.2% in the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after buying an additional 1,561 shares in the last quarter. Finally, Fred Alger Management LLC grew its stake in shares of Stryker by 415.8% during the 4th quarter. Fred Alger Management LLC now owns 24,011 shares of the medical technology company's stock valued at $8,664,000 after purchasing an additional 19,356 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.